HSD17B4

Across TCGA pan-cancer cohorts, HSD17B4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HSD17B4 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HSD17B4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where HSD17B4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.605	0.996	.012	18	view →
PDAC	OS	Quartile	III,IV	0.977	0.478	.018	10	view →
HNSC	OS	Median	All	1.000	0.938	.006	7	view →
UCEC	DFS	Median	II,III,IV	0.870	0.546	.047	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.602	1.000	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HSD17B4–LUAD (DFS)

Open the LUAD breakdown →